| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
| Teikoku Seiyaku Co., Ltd. | ||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
| Kissei Wellnet Corporation | ||||||||
|
|
Established: April 1, 2004 (Heisei 16)
Launch of uterine fibroid treatment drug "Esserti"
Kissei Pharmaceutical Co., Ltd. announced that the interim summary results of the post-marketing surveillance of Tabris, a drug for treating persistent and chronic immune thrombocytopenia (ITP), were approved at the 68th ASH Annual Meeting and Exposition held in the United States from December 12 to 15, 2026.
Kissei Pharmaceutical Co., Ltd. announced that it will implement personnel changes effective December 1, 2026. Mr. Yasuhiko Kirizawa of the Legal Department will assume the roles of Managing Executive Officer, Head of the Legal Department, Head of the Compliance Promotion Office, and Chief Legal Officer (CLO). Mr. Kazunari Uchimura of the Public Relations Department will become the Head of the Public Relations Department and Chief Communications Officer (CCO).
On October 21, 2026, at the Pharmaceutical Second Committee of the Pharmaceutical Affairs Review Board, the Ministry of Health, Labour and Welfare reported that it had reviewed our company's response document based on the reporting order. As a result of the deliberation, it was confirmed that there may be issues with the reliability of the documents submitted during the approval review.
Kissei Pharmaceutical Industries Co., Ltd. announced that it has confirmed unauthorized access by a third party to its group company Kissei Trading, and is investigating the scope of impact, including the leakage of confidential information. It apologized for the great inconvenience and concern caused by this incident.
Kissei Pharmaceutical Co., Ltd. will launch Zerifast, a hydration jelly mix, on November 10, 2026. Simply mix it with water or tea to make jelly; no heating or cooling is required. It can be prepared quickly and supports everyday hydration.
Kissei Pharmaceutical Co., Ltd. will make organizational and personnel changes effective October 1, 2026. Nobuko Yanagi will become Director and General Manager of the General Affairs Department, and Yasuhiko Kirisawa will become Senior Executive Officer and General Manager of the Legal Affairs Department.
Kissei Pharmaceutical announced that results of the international joint Phase III clinical trial of cretostimogene grenadenorepvec, a treatment for bladder cancer, were published in the medical journal The Lancet Oncology.
Kissei Pharmaceutical Industry announced that the European Commission revoked the sales approval for Tabneos on August 4, 2026. This was due to concerns about the integrity of clinical trial data from the European Medicines Agency.
Kissei Pharmaceutical Industry has contributed 10 million yen in relief funds through the Japanese Red Cross Society for the damage caused by the Kumamoto Earthquake in Reiwa 8. We hope for the reconstruction of the lives of the victims and the revival of the community.
Kissei Pharmaceutical Industry has been selected for the highest rating of 'A List' by CDP for its efforts and disclosure on climate change in 2025. It has also received an 'A-' rating for water security. The company is working on climate change and water resource circulation through environmental management promotion and group collaboration.